INTRODUCTION
Cancer remains, despite therapeutic advances, one of the foremost multifactorial diseases in terms of mortality. In 2012, 14.1 million worldwide new cases were reported, with 8.2 million deaths. 1 According to literature, metallodrugs are considered to be promising anticancer agents. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The development of these products was initially stimulated by the discovery of cisplatin, which is currently used to treat various types of cancer, in particular testicular, ovarian and non-small-cell lung cancers. [18] [19] [20] New classes of platinum complexes with lower toxicity or better activity have been synthesized. More than 50% of current treatments for cancer involve coordination compounds of platinum. [20] [21] [22] However, it has not been possible to eradicate a number of serious secondary effects caused by these medications, in particular their high level of general toxicity and tendency to induce resistance. 20 Inspired by the success of platinum compounds, other transition metals have been intensively studied, most recently in organometallic form, for example with Fe, 12, 13, 16, [23] [24] [25] [26] Ru, 3, [27] [28] [29] [30] Au, 8 Os, 15, 31 Ir, 32 rhodium, 33, 34 and some of these have now reached the clinical trial stage. 6, 35 Fe OH O(CH 2 ) 3 NMe 2 Fc-OH-TAM Chart 1. Fc-OH-TAM In the case of ferrocene compounds, we found that substituting ferrocenyl for the -aryl group of hydroxytamoxifen, an antiestrogenic drug for treatment of hormone dependent breast cancer, gave the organometallic compound (Fc-OH-TAM), which bears a [ferrocenyl-ene-phenol] redox motif (Jaouen-Top redox motif) and shows good activity against MDA-MB-231 triple negative breast cancer cells (TNBC) (Chart 1). The IC 50 value of Fc-OH-TAM is 0.5 M. 36 An update on this series of compounds, including the latest mechanistic results, was recently published by Jaouen et al.. 37 We also studied the series of ansa-ferrocenes bearing a three-carbon bridge. These compounds showed higher efficacity in vitro than those of the acyclic ferrocene series. For example, compounds 1b, 2b, 3b, and 4b are respectively 7, 3, 8 and 9 times more active than 1a, 2a, 3a, and 4a (Table 1) [a] 0.09±0.01 [b] 2a, 2b OH H 1.54±0.13 [c] 0.47±0.06 [c] 3a, 3b H H 7.54±0.7 [c] 0.92±0.11 [c] 4a, 4b NH 2 OH 0.55±0.05 [c] 0.061±0.005 [c] [a] Data from ref 39 , [b] Data from ref 40 , [c] Data from ref 38 .
The ansa compounds shown in Table 1 still display the above redox motif and are characterized by a three-carbon bridge. Ansa ferrocenes may exist and do exist in fact with different bridging chain lengths. One might assume in principle that the antiproliferative activity of these compounds would vary according to the length of the intercyclopentadienyl bridge, thus it is important to study ansa compounds with each length of bridging chain. We present here the syntheses and antiproliferative results of compounds with 4-and 5-carbon chains. In addition, we found that the ruthenocene derivatives are much less active than their ferrocene analogs. 30, 41 These characteristics as a whole have been evaluated and contextualized.
RESULTS AND DISCUSSION

Synthesis
Compounds 8-12 were prepared via a McMurry cross-coupling reaction between two appropriate ketones (Scheme 1). The compounds 3-methyl- [3] ferrocenophan-1-one, 5 42 and [5] ferrocenophan-1-one 7 43 were prepared according to literature methods. [4] ferrocenophan-1-one, 6, was originally synthesized via a homologation reaction using diazomethane as reagent 44 . However for safety reasons we chose to replace the diazomethane with TMSCHN 2 /BF 3 .Et 2 O in the synthesis of 6 44 . 
Antiproliferative activity
The antiproliferative activity of the compounds synthesized was measured on the TNBC (Triple Negative Breast Cancer) cell line MDA-MB-231. The IC 50 and log P o/w values are listed in Table 2 . Comparison of the antiproliferative activity of the diphenols 1b, 8, and 10 on the one hand, and compounds 2b, 9, and 11, on the other, clearly shows that the compounds bearing the shortest bridging chains are the most active while the compounds with 4-and 5-carbon bridges have similar activities to one another although higher than those of the previous series. In fact, 1b and 2b (n = 1) are respectively 27 and 9 times more active than 8 and 9 (n = 2). Conversely, 10 and 11 (n = 3) are slightly better than 8 and 9. It is surprising to note that the presence of a small lipophilic group, such as the methyl radical, on the bridge decreases the activity of the compound. This is the case for compound 12, which becomes less active than 1b. Moreover, we observed a clear difference between the two chiral isomers (R)-12 and We next compare the antiproliferative activity of the ferrocenophane series with that of the ruthenocenophane series. Table 3 shows the corresponding IC 50 values. The results clearly show a significant difference in antiproliferative activity between the two series. In fact, unlike ferrocenophane 1b, the ruthenocenophane equivalent 13 is practically inactive, and the IC 50 value is estimated in this case at more than 30 M. In addition, it is surprising that compound 14, which is bulkier than 1b due to the presence of the second -[bis(hydroxyphenyl)]methylidene group, still remains distinctly active (IC 50 = 2.7 ± 0.3 M).
This can be explained by the effect induced by the phenols. In fact, we have previously shown that for this type of compounds, the presence of two phenols resulted in an improvement in the antiproliferative effect compared to compounds bearing only one phenol, or indeed no phenol. 38, 45, 46 The low activity of ruthenocene compounds compared to that of ferrocene compounds, is confirmed yet again by the low activity of compound 15. Its IC 50 value is estimated to be around 10 M.
Discussion
We have recently shown that in oxidative activation of ferrocenes, the key metabolite, responsible for the majority of the antiproliferative activity, can differ. 12, 37 This sometimes arises because of the nature of the metal; for example with Fc-OH-Tam 16 the key metabolite is the moderately electrophilic quinone methide 17 (Scheme 4). [47] [48] [49] [50] But if the ferrocene is replaced by an osmocene 18 the active electrophilic species becomes a stabilized carbenium ion 19, and the IC 50 of the precursor on MDA-MB-231 goes from 0.5 µM to 3 µM. 51 In this situation the substituents also play a role, since if the alkyl chain in Fc-diOH 1a is substituted by -CH 2 CH 2 CH 2 OH, compound 20, the quinone methide is obtained with generation of a tetrahydrofuranyl-type heterocycle 21 and the IC 50 value on MDA-MB-231 goes from 0.6 µM to 0.11 µM. 52 In fact this new type of quinone methide permits only 1,6 Michael adducts and In the case of 3-carbon ansa derivatives, a certain number of parallels with Fc-diOH 1a can be seen. The two compounds generate ROS 53 and offer dual mechanisms, senescence and apoptosis 54, 55 depending on concentration. 37 They can be formulated as lipoid nanocapsules (LNC) and are active on cancer cells. [56] [57] [58] [59] They also possess an electrochemically oxidizable Fe (II). 48, 60, 61 However the 3-carbon ansa derivative 1b remains more active on MDA-MB-231, as well as on the NCI-60 cell lines, 38, 45, 46 than the acyclic form. 38, 46 In the case of the ansa derivative we were unable to characterize or isolate a species of the quinone methide type 60 suggesting that the oxidized form is more active and less stable than in the acyclic series. Indeed the X-ray crystal structure of a 3-carbon ansa species reveals a constrained arrangement in which the two Cp rings are not parallel but instead make an angle of 10°. 45 This non-planar arrangement is an indication of significant internal energy stored in the active intermediate that could be the constrained radical species below, 22, which is probably very active (Chart 2). Theoretical studies of this novel intermediate species confirm this idea. 62 The ferrocifens have already demonstrated their ability to change their key active species during oxidation but overall a fairly high level of cytotoxic activity is always observed. Lengthening the chain to relieve the crowding of the ansa molecule leads to behavior closer to that of the acyclic system. In fact chemical oxidation by silver oxide of compound 9 with 4 carbons and compound 11 with 5 carbons gives, as in the case of the acyclic series, quinone methides 23 and 24, respectively (Scheme 5). This behavior is consistent with the observed biological results.
With the derivatives of Ru, IC 50 values on cancer cells are found to be considerably superior to those obtained with Fe (for example with 13). Ruthenocene's lower anticancer activation relative to ferrocene in ferrocifen-type systems has already been reported. 51, 63 It may be linked to a redox system with less favorable reversibility. This difference may however be useful one. It has recently been shown that ferrocifens, in addition to their anticancer effect, in fact also show antiproliferative activity on plasmodium falciparum. 64 Indeed certain Ru complexes that are less active on cancer cells conserve good antimalarial
properties. 46 We are actively searching for molecules where the two properties are well differentiated. The Ru products reported here could form a part of this research into differentiated effects, 64 with a focus on antimalarial properties which have not previously been seen in the metallocifens.
This contribution is an illustration of the richness of the metallocifen series, as part of the exponentially developing branch of chemical biology that is the bioorganometallic chemistry of transition metals.
CONCLUSION
The antiproliferative effect of the diphenolic ansa derivatives of ferrocene on TNBC-type cancer cells such as MDA-MB-231 is largely dependent on the length of the carbon chain linking the two cyclopentadienyl rings, and occurs via an evolution of the mechanism of action that depends on the nature of the key metabolite. In the case of a three-carbon chain which constrains the molecule internally, the active species is not a moderately electrophophilic quinone methide such as that identified for Fc-diOH 1a but rather a constrained intermediate, probably of the radical type, which is more active than a neutral quinone methide. This constraint can be released by lengthening the chain to 4 or 5 carbons, which gives access to a quinone methide whose effect can be modulated by steric means.
Replacing Fe with Ru gives entities with a greatly reduced antiproliferative effect, confirming the better access to reversible redox of Fe relative to Ru in the action of ferrocifens. However
Ru complexes may be of use in offering antimalarial effects dissociated from antitumoral activity. This will be the subject of further studies.
EXPERIMENTAL
All reactions and manipulations were carried out under a nitrogen atmosphere using [3] ruthenocenophan-1-one 67 and R-and S-3-methyl- [3] ferrocenophan-1-one 42 2.41 (m, 2H, CH 2 ), 4.88 (t, J = 1.9 Hz, 4H, C 5 H 4 ), 5,07 (t, J = 1.9 Hz, 4H, C 5 H 4 ). 13 
Synthesis of (R)-1-[bis-(4-hydroxyphenyl)methylidene]-3-methyl-[3]ferrocenophane, (R)-12
Titanium (IV) chloride (0.564 g, 0.326 mL, 3 mmol) was added dropwise to a suspension of zinc powder (0.384 g, 5.9 mmol) in 12 mL of dry THF at 0°C. The mixture was heated at reflux for 1 hour. After cooling to room temperature anhydrous pyridine (0.472 mg, 0.482 mL, 6 mmol) and a solution of (R)-3-methyl- [3] ferrocenophan-1-one (0.254 g, 1 mmol) and 4,4'-dihydroxybenzophenone (0.214 g, 1 mmol) in 4 mL of THF were successively added and the resulting mixture was refluxed for 2h. After cooling to room temperature 30 ml of 8% potassium carbonate was added and the product was extracted with several portions of 50 ml 
Synthesis of (S)-1-[bis-(4-hydroxyphenyl)methylidene]-3-methyl-[3]ferrocenophane, (S)-
12
The synthetic procedure of S-12 is similar to that of R-12, starting from (S)-3-methyl- 
Synthesis of 1-[bis-(4-hydroxyphenyl)methylidene]-[4]ferrocenophane, 8
Titanium (IV) chloride (0.24 mL, 2.2 mmol) was added dropwise to a suspension of zinc powder (0.51 g, 7.8 mmol) in 10 mL of THF at 0°C. The mixture was heated at reflux for 1 hour. A second solution was prepared by dissolving [4] ferrocenophan-1-one (0.34 g, 1.3 mmol) and 4,4'-dihydroxybenzophenone (0.56 g, 2.7 mmol) in THF. This latter solution was added dropwise to the first solution and then the reflux was continued for 2 hours. After cooling to room temperature, the mixture was stirred with water and dichloromethane. The organic layer was acidified with a 1 N HCl solution, washed with brine, then dried over magnesium sulfate. After concentration under reduced pressure, the crude product was chromatographed on silica gel column, with a mixture of cyclohexane/ethyl acetate 
Synthesis of 1-[(4-hydroxyphenyl)phenylmethylidene]-[4]ferrocenophane, 9
The synthetic procedure of 9 is similar to that of 8. 
Synthesis of 1-[bis-(4-hydroxyphenyl)methylidene]-[5]ferrocenophane, 10
The synthetic procedure of 10 is similar to that of 8. Titanium (IV) chloride (1.061 g, 0.61 mL, 5.6 mmol.) was added dropwise to a suspension of zinc powder (0.512 g, 7.8 mmol.) in dry THF (30 mL) at 10-20°C. The mixture was heated at reflux for 2 hours. A second solution was prepared by dissolving [5] ferrocenophan-1-one (0.3 g, 1.12 mmol.) and 4,4'dihydroxybenzophenone (0.36 g, 1.7 mmol.) in dry THF (15 mL) . This latter solution was added dropwise to the first solution and then the reflux was continued for 2 hours. After cooling to room temperature, the mixture was stirred with water and dichloromethane. The mixture was acidified with diluted hydrochloric acid until dark color disappeared and was decanted. The aqueous layer was extracted with dichloromethane and the combination of organic layers was dried on magnesium sulfate. After concentration under reduced pressure, the crude product was chromatographed on silica gel column with a 90/10 dichloromethane/acetone solution as an eluent to afford 10 as an orange solid (0.160 g, 32% yield 
Synthesis of 1-[(4-hydroxyphenyl)phenylmethylidene]-[5]ferrocenophane, 11
The synthetic procedure of 11 is similar to that of 8. Titanium (IV) chloride (0.38 mL, 3.5 mmol), zinc powder (0.73 g, 11.2 mmol), dry THF (40 mL), [5] ferrocenophan-1-one (0.5 g, 1.9 mmol), 4-hydroxybenzophenone (0.74 g, 3.7 mmol), reflux time: 17 hours. After cooling to room temperature, the mixture was stirred with water and dichloromethane. The crude product was chromatographed on silica gel column, with a mixture of pentane/ethyl acetate 
Synthesis of 1-[bis-(4-hydroxyphenyl)methylidene]-[3]ruthenocenophane, 13
The synthetic procedure of 13 is similar to that of 8. 
Synthesis of 1,3-bis-[bis-(4-hydroxyphenyl)methylidene]-[5]ferrocenophane, 14
The synthetic procedure of 14 is similar to that of 8. 
Synthesis of 1,3-bis-[bis-(4-hydroxyphenyl)methylidene]-[5]ruthenocenophane, 15
The synthetic procedure of 15 is similar to that of 8. 
Typical procedure of oxidation with Ag 2 O
Substrate (around 20 mg, 1 equiv.) was dissolved in 1 mL of acetone-d 6 . Freshly prepared silver oxide (5 equiv.) was added and the mixture was sonicated for 1-2h until total conversion of the starting material. Silver oxide was removed by centrifugation (6 min., 3500 rpm) and the solution was transferred immediately into an NMR tube. Compounds with M = Fe, n = 3 are the most active ones.
1-([2,5-Dien-4-oxo-cyclohexanilidenyl]phenyl)methyl-1,4-(ferrocene-1,1'-diyl)-but-1-ene,
